<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03868462</url>
  </required_header>
  <id_info>
    <org_study_id>OPT1029</org_study_id>
    <nct_id>NCT03868462</nct_id>
  </id_info>
  <brief_title>Optos P200TE Agreement and Precision Study</brief_title>
  <official_title>Optos P200TE Agreement and Precision Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Optos, PLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Optos, PLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a prospective comparative, randomized, single center study to assess agreement
      and precision of the Optos P200TE in comparison to the predicate device in normal subjects,
      subjects with glaucoma, and subjects with retinal disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 11, 2019</start_date>
  <completion_date type="Actual">September 16, 2019</completion_date>
  <primary_completion_date type="Actual">September 16, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Limit of Agreement (LOA) between the Optos P200TE and predicate device measurements of full retinal thickness (μm).</measure>
    <time_frame>At the end of Visit 1 or optional Visit 2 (each visit is 1 day)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Limit of Agreement (LOA) between the Optos P200TE and predicate device measurements of retinal nerve fiber layer thickness (μm).</measure>
    <time_frame>At the end of Visit 1 or optional Visit 2 (each visit is 1 day)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Limit of Agreement (LOA) between the Optos P200TE and predicate device measurements of ganglion cell complex thickness (μm).</measure>
    <time_frame>At the end of Visit 1 or optional Visit 2 (each visit is 1 day)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Limit of Agreement (LOA) between the Optos P200TE and predicate device measurements of optic disc (area, volume, cup-to-disc ratio).</measure>
    <time_frame>At the end of Visit 1 or optional Visit 2 (each visit is 1 day)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Precision between the Optos P200TE and predicate device measurements of full retinal thickness.</measure>
    <time_frame>At the end of Visit 1 or optional Visit 2 (each visit is 1 day)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Precision between the Optos P200TE and predicate device measurements of retinal nerve fiber layer thickness.</measure>
    <time_frame>At the end of Visit 1 or optional Visit 2 (each visit is 1 day)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Precision between the Optos P200TE and predicate device measurements of ganglion cell complex thickness.</measure>
    <time_frame>At the end of Visit 1 or optional Visit 2 (each visit is 1 day)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Precision between the Optos P200TE and predicate device measurements of optic disc (area, volume, cup-to-disc ratio).</measure>
    <time_frame>At the end of Visit 1 or optional Visit 2 (each visit is 1 day)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Precision of the P200TE for the super pixel grid measurements of the full retinal thickness.</measure>
    <time_frame>At the end of Visit 1 or optional Visit 2 (each visit is 1 day)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Precision of the P200TE for the super pixel grid measurements of the RNFL thickness.</measure>
    <time_frame>At the end of Visit 1 or optional Visit 2 (each visit is 1 day)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Precision of the P200TE for the super pixel grid measurements of GCC thickness.</measure>
    <time_frame>At the end of Visit 1 or optional Visit 2 (each visit is 1 day)</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">137</enrollment>
  <condition>Retinal Disease</condition>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>Optical Coherence Tomography (OCT)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Optos P200TE</intervention_name>
    <description>The P200TE Ophthalmoscope provides widefield Scanning Laser Ophthalmoscope (SLO) fundus imaging and Optical Coherence Tomography (OCT) imaging in one device.</description>
    <arm_group_label>Optical Coherence Tomography (OCT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Predicate Device</intervention_name>
    <description>The predicate device is an optical coherence tomography system intended for in vivo imaging, axial cross-sectional, three-dimensional imaging and measurement of anterior and posterior ocular structures.</description>
    <arm_group_label>Optical Coherence Tomography (OCT)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for Normal Group

          1. Subjects 22 years of age or older on the date of informed consent

          2. Subjects able to understand the written informed consent and willing to participate as
             evidenced by signing the informed consent

          3. Subjects with normal eye examinations in both eyes on the date of the study visit as
             observed with a 90 diopter lens

          4. BCVA 20/40 or better (each eye) on the date of the study visit

             Exclusion Criteria for Normal Group

          5. Subjects unable to tolerate ophthalmic imaging

          6. Subjects with ocular media not sufficiently clear to obtain acceptable OCT images in
             either eye

          7. Presence of any ocular pathology except for cataract in either eye

          8. History of leukemia, dementia or multiple sclerosis

             Inclusion Criteria for Glaucoma Group

          9. Subjects 22 years of age or older on the date of informed consent

         10. Subjects able to understand the written informed consent and willing to participate as
             evidenced by signing the informed consent

         11. BCVA 20/40 or better in the study eye

         12. History of Visual field defects within the previous six (6) months from the study
             visit or measured the day of the study visit consistent with glaucomatous optic nerve
             damage with at least one of the following two findings:

               1. On pattern deviation (PD), there exists a cluster of 3 or more points in an
                  expected location of the visual field depressed below the 5% level, at least 1 of
                  which is depressed below the 1% level;

               2. Glaucoma hemi-field test &quot;outside normal limits.&quot;

         13. Glaucomatous optic nerve damage as evidenced by any of the following optic disc or
             retinal nerve fiber layer structural abnormalities:

               1. Diffuse thinning, focal narrowing, or notching of the neuroretinal rim,
                  especially at the inferior or superior poles with or without disc hemorrhage;

               2. Optic disc neural rim asymmetry of the two eyes consistent with loss of neural
                  tissue

             Exclusion Criteria for Glaucoma Group

         14. Subjects unable to tolerate ophthalmic imaging

         15. Subjects with ocular media not sufficiently clear to obtain acceptable OCT images in
             the study eye

         16. No reliable Humphrey Field Analyzer (HFA) visual field (24-2 Sita Standard, white on
             white) result within 6 months of the study visit, defined as fixation losses &gt; 33% or
             false positives &gt; 33%, or false negatives &gt; 33% in the study eye

         17. Presence of any ocular pathology except glaucoma in the study eye

         18. History of leukemia, dementia or multiple sclerosis

             Inclusion Criteria for Retina Disease Group

         19. Subjects 22 years of age or older on the date of informed consent

         20. Subjects able to understand the written informed consent and willing to participate as
             evidenced by signing the informed consent

         21. Subjects presenting at the site with retinal disease

         22. BCVA 20/400 or better in the study eye

         23. Diagnosis of some type of retinal pathology by investigator, may include, but not
             limited to: Macular Degeneration (including patients with drusen and geographic atropy
             and choroidal neovascularization), Diabetic Macular Edema, Diabetic Retinopathy,
             Macular Hole, Epiretinal Membrane, Central Serous Retinopathy and others

             Exclusion Criteria for Retinal Disease Group

         24. Subjects unable to tolerate ophthalmic imaging

         25. Subject with ocular media not sufficiently clear to obtain acceptable OCT images in
             the study eye

         26. Presence of glaucoma or any ocular pathology other than a retinal pathology (e.g.,
             cornea pathology) in the study eye as determined by self-report and/or investigator
             assessment at the study visit;

         27. History of leukemia, dementia or multiple sclerosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>New England Retina Consultants</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>March 2, 2019</study_first_submitted>
  <study_first_submitted_qc>March 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 11, 2019</study_first_posted>
  <last_update_submitted>October 13, 2019</last_update_submitted>
  <last_update_submitted_qc>October 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

